{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:50:45Z","timestamp":1789681845023,"version":"4.0.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024370","name":"MIUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tips.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T20:14:04Z","timestamp":1754511244000},"page":"836-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Human carbonic anhydrase modulators: the past, present, and future"],"prefix":"10.1016","volume":"46","author":[{"given":"Simone","family":"Giovannuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.07.002_bb0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.07.002_bb0010","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543776.2018.1523897","article-title":"Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas","volume":"28","author":"Supuran","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0020","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.bmc.2007.04.020","article-title":"Carbonic anhydrases as targets for medicinal chemistry","volume":"15","author":"Supuran","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/acs.chemrev.4c00278","article-title":"Multiple binding modes of inhibitors to human carbonic anhydrases: an update on the design of isoform-specific modulators of activity","volume":"125","author":"D'Ambrosio","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129411","article-title":"A simple yet multifaceted 90-year-old, evergreen enzyme: carbonic anhydrase, its inhibition and activation","volume":"93","author":"Supuran","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.07.002_bb0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0271678X17699224","article-title":"Carbonic anhydrase inhibitors modify intracellular pH transients and contractions of rat middle cerebral arteries during CO2\/HCO3- fluctuations","volume":"38","author":"Rasmussen","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.tips.2025.07.002_bb0040","article-title":"pH regulating mechanisms of astrocytes: a critical component in physiology and disease of the brain","volume":"120","author":"Theparambil","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.tips.2025.07.002_bb0045","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1080\/14756366.2022.2121393","article-title":"Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities","volume":"37","author":"Supuran","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/metabo8020025","article-title":"Carbonic anhydrases and metabolism","volume":"8","author":"Supuran","year":"2018","journal-title":"Metabolites"},{"key":"10.1016\/j.tips.2025.07.002_bb0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1517\/13543776.2013.790957","article-title":"Antiobesity carbonic anhydrase inhibitors: a literature and patent review","volume":"23","author":"Scozzafava","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.124.001125","article-title":"Multi- and polypharmacology of carbonic anhydrase inhibitors","volume":"77","author":"Supuran","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: chemistry, physiology, and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0070","first-page":"S61","article-title":"Physiology and molecular biology of renal carbonic anhydrase","volume":"15","author":"Schwartz","year":"2002","journal-title":"J. Nephrol."},{"key":"10.1016\/j.tips.2025.07.002_bb0075","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2021-319530","article-title":"Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?","volume":"106","author":"Stoner","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.002_bb0080","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.3390\/molecules26216380","article-title":"Carbonic anhydrase inhibitors and epilepsy: state of the art and future perspectives","volume":"26","author":"Ciccone","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2025.07.002_bb0085","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/biom10091307","article-title":"Effects of new NSAID-CAI hybrid compounds in inflammation and lung fibrosis","volume":"10","author":"Lucarini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2025.07.002_bb0090","first-page":"7075","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.07.002_bb0095","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.3390\/ijms20194724","article-title":"A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer's disease","volume":"20","author":"Provensi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.07.002_bb0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpain.2014.01.001","article-title":"Inhibition of carbonic anhydrase augments GABAA receptor-mediated analgesia via a spinal mechanism of action","volume":"15","author":"Asiedu","year":"2014","journal-title":"J. Pain"},{"key":"10.1016\/j.tips.2025.07.002_bb0105","first-page":"F306","article-title":"Acid excretion by bicarbonate-free perfused rat kidney","volume":"240","author":"Garvey","year":"1981","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.tips.2025.07.002_bb0110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10741-024-10417-7","article-title":"Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Milbradt","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3122\/jabfm.2023.230379R0","article-title":"Acetazolamide as a valuable addition to acute heart failure?","volume":"37","author":"Ge","year":"2024","journal-title":"J. Am. Board Fam. Med."},{"key":"10.1016\/j.tips.2025.07.002_bb0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11886-025-02257-0","article-title":"Use of acetazolamide in people with decompensated heart failure: a systematic review and meta-analysis","volume":"27","author":"Erazo-Castillo","year":"2025","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.tips.2025.07.002_bb0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/13543776.2019.1679117","article-title":"Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019","volume":"29","author":"Supuran","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0130","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00002512-199710050-00006","article-title":"Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension","volume":"10","author":"Balfour","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.tips.2025.07.002_bb0135","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","article-title":"Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension","volume":"20","author":"Cvetkovic","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.tips.2025.07.002_bb0140","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/13543776.2019.1665023","article-title":"Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)","volume":"29","author":"Nocentini","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543776.2019.1661992","article-title":"Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)","volume":"29","author":"Angeli","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/13543776.2019.1670812","article-title":"Rho-kinase inhibitors in the management of glaucoma","volume":"29","author":"Berrino","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2025.07.002_bb0155","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1055\/s-2007-1024597","article-title":"Acetazolamide and high altitude diseases","volume":"13","author":"Bradwell","year":"1992","journal-title":"Int. J. Sports Med."},{"key":"10.1016\/j.tips.2025.07.002_bb0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hrtlng.2003.08.002","article-title":"High-altitude-related disorders--part I: pathophysiology, differential diagnosis, and treatment","volume":"32","author":"Rodway","year":"2003","journal-title":"Heart Lung J. Acute Crit. Care"},{"key":"10.1016\/j.tips.2025.07.002_bb0165","first-page":"667","article-title":"H+ transport from CNS in hypercapnia and regulation of CSF [HCO3-]","volume":"42","author":"Kazemi","year":"1977","journal-title":"J. Appl. Physiol. Respir. Environ. Exerc. Physiol."},{"key":"10.1016\/j.tips.2025.07.002_bb0170","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1152\/japplphysiol.01572.2005","article-title":"Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness","volume":"102","author":"Leaf","year":"2007","journal-title":"J. Appl. Physiol. (Bethesda, Md.: 1985)"},{"key":"10.1016\/j.tips.2025.07.002_bb0175","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/106002809603000515","article-title":"Acetazolamide in the treatment of seizures","volume":"30","author":"Reiss","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tips.2025.07.002_bb0180","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/NDT.S512","article-title":"Topiramate in the treatment of partial and generalized epilepsy","volume":"3","author":"Faught","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.tips.2025.07.002_bb0185","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cns.12418","article-title":"Zonisamide: review of recent clinical evidence for treatment of epilepsy","volume":"21","author":"Kwan","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0190","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2165\/00003495-199754050-00009","article-title":"Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy","volume":"54","author":"Langtry","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2025.07.002_bb0195","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1042\/CS20210040","article-title":"Emerging role of carbonic anhydrase inhibitors","volume":"135","author":"Supuran","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.tips.2025.07.002_bb0200","article-title":"Sulthiame add-on therapy for epilepsy","volume":"8","author":"Bresnahan","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2025.07.002_bb0205","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","article-title":"Narrative review of topiramate: clinical uses and pharmacological considerations","volume":"40","author":"Pearl","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-3-642-24716-3_20","article-title":"Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide","volume":"209","author":"Antel","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.tips.2025.07.002_bb0215","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ph3082398","article-title":"Combinations of drugs in the treatment of obesity","volume":"3","author":"Halpern","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2025.07.002_bb0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/14728214.13.2.383","article-title":"Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity","volume":"13","author":"Supuran","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.tips.2025.07.002_bb0225","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bioorg.2018.02.021","article-title":"Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy","volume":"77","author":"Nocentini","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0230","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3892\/or.2021.8179","article-title":"Uncovering the interplay between pH receptors and immune cells: potential drug targets (review)","volume":"46","author":"Cao","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tips.2025.07.002_bb0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1165\/rcmb.2018-0232OC","article-title":"Carbonic anhydrase inhibition ameliorates inflammation and experimental pulmonary hypertension","volume":"61","author":"Hudalla","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tips.2025.07.002_bb0240","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1124\/jpet.104.082776","article-title":"Acetazolamide, a carbonic anhydrase inhibitor, reverses inflammation-induced thermal hyperalgesia in rats","volume":"313","author":"Radhakrishnan","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0245","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/acs.jmedchem.6b01607","article-title":"Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis","volume":"60","author":"Bua","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0250","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/acs.jmedchem.8b00420","article-title":"Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis","volume":"61","author":"Akgul","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0255","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2174\/138161208783877938","article-title":"Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs","volume":"14","author":"Dogn\u00e9","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tips.2025.07.002_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.07.114","article-title":"Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)","volume":"478","author":"Kim","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2025.07.002_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2201407","article-title":"Identification of new 4-(6-oxopyridazin-1-yl)benzenesulfonamides as multi-target anti-inflammatory agents targeting carbonic anhydrase, COX-2 and 5-LOX enzymes: synthesis, biological evaluations and modelling insights","volume":"38","author":"Badawi","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0270","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0275","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expt. Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2025.07.002_bb0280","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.07.002_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136873","article-title":"Exploring the binding mode of phenyl and vinyl boronic acids to human carbonic anhydrases","volume":"282","author":"Esposito","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.tips.2025.07.002_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106976","article-title":"Boron-containing carbonic anhydrases inhibitors","volume":"143","author":"Giovannuzzi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0295","first-page":"1498","article-title":"Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity","volume":"34","author":"Langella","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/acsmedchemlett.4c00562","article-title":"Tetrazole is a novel zinc binder chemotype for carbonic anhydrase inhibition","volume":"16","author":"Giovannuzzi","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.07.002_bb0305","doi-asserted-by":"crossref","first-page":"18221","DOI":"10.1021\/acs.jmedchem.4c01516","article-title":"Benzoxaborinine, new chemotype for carbonic anhydrase inhibition: ex novo synthesis, crystallography, in silico studies, and anti-melanoma cell line activity","volume":"67","author":"Giovannuzzi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0310","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2012.08.024","article-title":"Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"64","author":"Stillebroer","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tips.2025.07.002_bb0315","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tips.2025.07.002_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.04.003","article-title":"STARLITE 1: Phase 1b\/2 study of combined 177Lu-girentuximab plus cabozantinib and nivolumab in treatment-na\u00efve patients with advanced clear-cell renal cell carcinoma","author":"Hasanov","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.tips.2025.07.002_bb0325","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2025.07.002_bb0330","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1002\/alz.13063","article-title":"FDA-approved carbonic anhydrase inhibitors reduce amyloid \u03b2 pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness","volume":"19","author":"Canepa","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.tips.2025.07.002_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.772278","article-title":"Carbonic anhydrases as potential targets against neurovascular unit dysfunction in Alzheimer's disease and stroke","volume":"13","author":"Lemon","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.tips.2025.07.002_bb0340","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12787","article-title":"Carbonic anhydrase inhibition selectively prevents amyloid \u03b2 neurovascular mitochondrial toxicity","volume":"17","author":"Solesio","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.tips.2025.07.002_bb0345","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.3390\/cells12242840","article-title":"Amyloid beta oligomers activate death receptors and mitochondria-mediated apoptotic pathways in cerebral vascular smooth muscle cells; protective effects of carbonic anhydrase inhibitors","volume":"12","author":"Anzovino","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tips.2025.07.002_bb0350","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.11.006","article-title":"The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain","volume":"86","author":"Fossati","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2025.07.002_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70023","article-title":"Carbonic anhydrase inhibitors prevent presymptomatic capillary flow disturbances in a model of cerebral amyloidosis","volume":"21","author":"Guti\u00e9rrez-Jim\u00e9nez","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.tips.2025.07.002_bb0360","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1161\/STROKEAHA.108.540765","article-title":"Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury","volume":"40","author":"Wang","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.tips.2025.07.002_bb0365","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/01.STR.26.7.1234","article-title":"Evaluation of the acetazolamide test. Vasoreactivity and cerebral blood volume","volume":"26","author":"Okudaira","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.tips.2025.07.002_bb0370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1378\/chest.13-2967","article-title":"Cerebral oxygenation in patients with OSA: effects of hypoxia at altitude and impact of acetazolamide","volume":"146","author":"Ulrich","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.tips.2025.07.002_bb0375","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41589-024-01762-7","article-title":"Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion","volume":"21","author":"Lopez","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2025.07.002_bb0380","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1021\/acs.jmedchem.4c00045","article-title":"Dual inhibitors of brain carbonic anhydrases and monoamine oxidase-B efficiently protect against amyloid-\u03b2-induced neuronal toxicity, oxidative stress, and mitochondrial dysfunction","volume":"67","author":"Giovannuzzi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0385","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1152\/jn.2001.85.1.269","article-title":"Theta rhythm of hippocampal CA1 neuron activity: gating by GABAergic synaptic depolarization","volume":"85","author":"Sun","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.tips.2025.07.002_bb0390","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0022-3565(24)29621-X","article-title":"Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats","volume":"297","author":"Sun","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0395","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuropharm.2017.03.009","article-title":"Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus","volume":"118","author":"Canto de Souza","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2025.07.002_bb0400","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13066","article-title":"Acetazolamide potentiates the afferent drive to prefrontal cortex in vivo","volume":"5","author":"Bueno-Junior","year":"2017","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.tips.2025.07.002_bb0405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuropharm.2012.11.031","article-title":"Acetazolamide impairs fear memory consolidation in rodents","volume":"67","author":"Yang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2025.07.002_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114828","article-title":"New \u03b2-arylchalcogeno amines with procognitive properties targeting carbonic anhydrases and monoamine oxidases","volume":"244","author":"Provensi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0415","doi-asserted-by":"crossref","first-page":"16873","DOI":"10.1021\/acs.jmedchem.4c01866","article-title":"Enhanced recognition memory through dual modulation of brain carbonic anhydrases and cholinesterases","volume":"67","author":"Nocentini","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0420","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bmc.2015.02.027","article-title":"A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects","volume":"23","author":"Carta","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0425","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14737175.2016.1193009","article-title":"Carbonic anhydrase inhibition and the management of neuropathic pain","volume":"16","author":"Supuran","year":"2016","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.tips.2025.07.002_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115783","article-title":"Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for \u03bc opioid receptor for safer and long-lasting analgesia","volume":"260","author":"Angeli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0435","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3109\/14756366.2015.1113407","article-title":"Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors","volume":"31","author":"Di Cesare Mannelli","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0440","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/14756366.2021.1907575","article-title":"Protective effects of carbonic anhydrase inhibition in brain ischaemia in vitro and in vivo models","volume":"36","author":"Dettori","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2025.07.002_bb0445","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.3390\/ijms22095029","article-title":"Role of carbonic anhydrase in cerebral ischemia and carbonic anhydrase inhibitors as putative protective agents","volume":"22","author":"Bulli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.07.002_bb0450","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.07.002_bb0455","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.2c01843","article-title":"Development of human carbonic anhydrase II heterobifunctional degraders","volume":"66","author":"O'Herin","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:17:29Z","timestamp":1757031449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0165614725001464"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.07.002","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human carbonic anhydrase modulators: the past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}